Activatin’ Human Adipose Progenitors in Obesity

Jaswinder K. Sethi

Obesity relates to the abnormal accumulation of body fat and is associated with a number of morbidities including diabetes, dyslipidemia, cardiovascular disease, and cancer. Great strides have been made in our understanding of the molecular basis for these associations, and a number of hypotheses have been put forward. One seemingly counterintuitive hypothesis is the “adipose tissue expandability hypothesis,” which suggests that the relative accumulation of adipose mass per se may not be directly causative in obesity-related metabolic abnormalities; instead, adipose tissue function and plasticity are the key determinants. Although adipose tissue is arguably the most plastic organ in our bodies, it cannot expand indefinitely—particularly in the face of years of chronic fuel surplus. Furthermore, when such a limit is reached, this would inevitably set a limit on the body’s capacity to safely store neutral triglycerides. Consequently, with continued nutritional overload, excess fat is deposited in ectopic sites, in tissues not specialized to store large amounts of triglycerides. The result is lipotoxicity and metabolic dysregulation of peripheral tissues (1). Similar metabolic consequences may also be predicted when one considers impaired adipose tissue function (dysregulated adipose metabolism and endocrinology) or indeed when there is a paucity of adipose tissue.

Recent evidence points to substantial adipose tissue remodeling, particularly in cases associated with metabolic dysregulation. Obese dysfunctional adipose tissue is characterized by adipocyte hypertrophy, increased angiogenesis, immune infiltration, increased extracellular matrix deposition/fibrosis, and chronic inflammation. In contrast, growth of healthy adipose tissue mass is determined by a complex coordination of adipocyte turnover (aP2+/CD68−), adipocyte cell number (aP2+/CD68−) is decreased in obese subjects. With the recent success in identifying and locating adipose progenitors in both murine and human tissues, it is hoped that these issues can now be addressed. Of note, bona fide multipotent adipose progenitors exhibit a distinct molecular signature, including the expression of stem cell markers (Lin−,CD29+,CD34+,Sca-1+,CD24+), developmental transcription factors, extracellular matrix genes, antiangiogenic factors, and signaling cascade components (3,8,9).

Many growth factors have been implicated in determining the size of progenitor pools (in embryonic and adult tissue). Some, such as Wnts, bone morphogenetic proteins (BMPs), and transforming growth factor (TGF)-β have also been implicated in regulating lineage determination and adipogenesis, primarily in rodent models. However, very few factors have been specifically demonstrated to promote proliferation of human adipose progenitors. In the accompanying original article, Zaragosi et al. (12) present their findings on activin A, a putative promoter of self-renewal and antiadipogenesis in human adipose progenitors.

Activins are members of the TGF-β protein superfamly of secreted growth factors, which includes BMPs, Nodal, and TGF-β. They act in a paracrine/autocrine manner to regulate cell proliferation, differentiation, and apoptosis during embryonic development, tissue remodeling, inflammatory immune response, wound repair, and reproduction. Activins exist in a number of dimeric configurations,
often associated with neutralizing binding proteins. Activin A is a homodimer of inhibin \( \alpha \) subunits encoded by the \( \text{INHBA} \) gene. Similarly, activins B, C, and E are homodimers of \( \text{INHBB} \), \( \text{INHBC} \), and \( \text{INHBE} \) gene products, respectively. Activin AB is heterodimer of inhibin \( \alpha \) and inhibin \( \beta \) subunits. Interestingly, the inhibin \( \beta A \) subunit is widely expressed, whereas the inhibin \( \beta B \) subunit is highly expressed in adipocytes, and the \( \beta C \) and \( \beta E \) subunits are predominantly expressed in the liver. To date, only activin B and activin E homodimers have been implicated in glucose homeostasis (10,11).

Zaragosi et al. now report that \( \text{INHBA} \) mRNA is not only detected in human adipose tissue, but unlike \( \text{INHBB} \), it is preferentially expressed in primary adipose progenitors (human multipotent adipose-derived stem [hMADS] cells and CD34+/CD31− stromal vascular fraction [SVF] cells) and localized to SVFs of omental, subcutaneous, and mesenteric white adipose depots. In vitro, activin A expression and secretion is required for optimal proliferation during cell propagation, but it is downregulated as cultured hMADS and primary human preadipocytes undergo adipogenic conversion (12). Although this observation seems consistent with the known mitogenic action of activin A (on embryonic and gonadal stem cells), it contrasts with a lack of effect on clonal expansion during murine preadipocyte differentiation (13,14).

As with most "preadipocyte" genes, activin A can inhibit adipogenesis in vitro (12–14). However, its mechanism of action seems to be context dependent. Previous reports have suggested that activin A targets CCAAT/enhancer-binding protein \( \beta \) (C/EBP\( \beta \)) activity (13,15). In contrast, Zaragosi et al. suggest that activin A prevents adipogenic induction of both C/EBP\( \beta \) isoforms (LAP and LIP). They further support this with evidence that C/EBP\( \beta \)-LAP overexpressing hMADS cells are resistant to the antiadipogenic actions of activin A (12). Further mechanistic insights are provided using both pharmacological inhibition of activin receptor kinase activity (ALK inhibitor SB-431542), as well as SMAD2 small interfering RNA. This is not only consistent with the limited knowledge of activin A–mediated signal transduction (Fig. 1), but also demonstrates that these signal transducers are involved in activin A–induced proliferation and antiadipogenesis in hMADS. What still remains unclear is the identity of the activin-induced SMAD2 target genes that inhibit C/EBP\( \beta \) expression and/or promote proliferation. Moreover, given the roles of activin A in nonadipose lineage determination (16,17), it also remains to be formally demonstrated that activin A does not alter the multipotency of human adipose progenitors. If multipotency of progenitors is lost after activin A treatment, this could represent the alternative possibility that in obese-inflamed adipose tissue, activin A plays a role in reducing adipogenic potential of progenitors but also promotes tissue fibrosis.

Zaragosi et al. also found that in the white adipose tissue of obese nondiabetic individuals, \( \text{INHBA} \) expression was
FIG. 2. Local autocrine and paracrine signals regulate progenitor proliferation and titrate adipogenesis. Remarkable parallels are emerging between the Wnt/β-catenin signaling network (A) and the activin signaling network (B). These suggest that maturing adipocytes may produce proadipogenic signals that inhibit progenitor proliferation and promote preadipocyte recruitment.
increased compared with that in lean individuals, although it is not clear whether these subjects are exhibiting the early hallmarks of adipose tissue inflammation. Further investigation suggests that in progenitors, activin A was induced by signals secreted from adipose tissue–derived CD34+/CD14+ cells (i.e., macrophages, monocytes, and polymorphonuclear neutrophils). Given that activin A is known to be regulated by proinflammatory cytokines (18), this potentially provides additional support for the notion that a proinflammatory environment contributes to limiting further adipose expansion (19). An additional fascinating observation is that activin A expression in adipose progenitors is reduced by the synthetic glucocorticoid dexamethasone. This presents the intriguing possibility that anti-inflammatory steroids may promote adiposity, in part, via downregulation of INHBA.

As with any new discovery, the report by Zaragosi et al. raises many new questions. For example, if activin A is important in the physiological regulation of adipose tissue growth, is its production regulated by nutritional cues and during the development of normal adiposity? How does the presence of proadipogenic activin B (from adipocytes) affect activin A bioactivity in adipose progenitors? Does the activin network mediate the paracrine cross talk between maturing adipocytes and preadipocytes as has been proposed for the Wnt network (Fig. 2 and ref. 20).

Given its ubiquitous expression and diverse biological functions, a detailed understanding of local/tissue-specific regulation of activin A activity is also required before we can consider it as a candidate for antiobesity therapeutics. In obesity, what proportions of adipose-derived activin A contribute to circulating levels? Are these levels influenced by sex or reproductive age, liver dysfunction or cancer? Does adipose expression and activity of activin A correlate inversely with adiposity, particularly in the absence of adipose inflammation? Is it differentially expressed in adipose tissue from obese healthy subjects relative to obese diabetic subjects? Finally, because the biological activity and bioavailability of activin A is influenced by the presence of functional antagonists and binding proteins, such as inhibins and follistatin (14), it will be pertinent to define the in vivo levels of activins, follistatin, and inhibins in the same subjects before making any inferences as to the potential consequences of differential expression in lean, obese, and obese-diabetic adipose tissue.

In summary, given that limitations in fat storage can lead to metabolic disorders, there is a clear need to decode the molecular mechanisms that regulate adipose tissue expandability and to discriminate between the normal physiological cues and those involved in the metabolic syndrome. Clearly, unlocking adipose-specific signals that prevent adipose progenitors from differentiating in response to nutritional surplus is attractive for biomarker discovery, targeted therapeutics, and tissue engineering alike. However, much remains to be addressed before activin A can be proposed as a candidate biomarker for obesity and/or a therapeutic target for the associated metabolic complications.

ACKNOWLEDGMENTS
No potential conflicts of interest relevant to this article were reported.

REFERENCES
1. Sethi JK, Vidal-Puig AJ. Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res 2007;48:1253–1262
2. Arner E, Westmark PO, Spalding KL, Britton T, Rydén M, Frisén J, Bernard S, Arner P. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes 2010;59:105–109
3. Lin G, Garcia M, Ning H, Banic L, Guo YL, Lue TF, Lin CS. Defining stem and progenitor cells within adipose tissue. Stem Cells Dev 2008;17:1053–1063
4. Pasarica M, Xie H, Hynel D, Bruy G, Greenway F, Ravussin E, Smith SR. Lower total adipocyte number but no evidence for small adipocyte depletion in patients with type 2 diabetes. Diabetes Care 2000;23:900–902
5. Permana PA, Nair S, Lee YH, Lucoy-Bachman G, Vezarova De Courten B, Tataranni PA. Subcutaneous abdominal preadipocyte differentiation in vitro inversely correlates with central obesity. Am J Physiol Endocrinol Metab 2004;286:E958–E962
6. Tchoukalova Y, Koutsarci C, Jensen M. Committed subcutaneous preadipocytes are reduced in human obesity. Diabetologia 2007;50:151–157
7. Isakson P, Hammarstedt A, Gustafson B, Smith U. Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes 2006;55:1550–1557
8. Lang K, Zeve D, Suh JM, Bomsakovski D, Kyba M, Harmer RE, Tallquist MD, Graff JM. White fat progenitor cells reside in the adipose vasculature. Science 2008;322:583–586
9. Rodeheffer MS, Birsoy K, Friedman JM. Identification of white adipocyte progenitor cells in vivo. Cell 2008;135:240–249
10. Bagerd S, Cruikshank M, Mour KM, Barrett P, Bashir S, Miller JD. Inhibin B expression in murine adipose tissue and its regulation by leptin, insulin and dexamethasone. J Mol Endocrinol 2009;43:171–177
11. Hashimoto O, Sekiyama K, Matsuo T, Hasegawa Y. Implication of activin E in glucose metabolism: transcriptional regulation of the inhibin/activin E subunit gene in the liver. Life Sci 2009;85:534–540
12. Zaragosi L-E, Wdziekonski B, Villageois P, Keophiphath M, Maumus M, Tataranni PA, Bernard S, Arner P. Adipocyte turnover: relevance to human adipose tissue morphology. Endocrinology 2002;143:74–83
13. Sethi JK, Vidal-Puig AJ. Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res 2007;48:1253–1262
14. Hirai S, Yamamika M, Kawachi H, Matsui T, Yano H. Activin A inhibits differentiation of 3T3-L1 preadipocyte. Mol Cell Endocrinol 2005;222:21–26
15. Hirai S, Matsumoto H, Morihi NH, Kawachi H, Yano H. Follistatin rescues the inhibitory effect of activin A on the differentiation of bovine preadipocyte. Domest Anim Endocrinol 2007;33:269–280
16. Zauberman A, Lapter S, Zipori D. Smad proteins suppress CCAAT/enhancer-binding protein (C/EBP) beta- and STA3-mediated transcriptional activation of the haptoglobin promoter. J Biol Chem 2001;276:24719–24725
17. Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 2002;143:74–83
18. Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vennuri MC, Rao MS, Tanavde V. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 2008;112:295–307
19. Takahashi S, Uchimaru K, Harigaya K, Asano S, Yamashita T. Tumor necrosis factor and interleukin-1 induce activin A gene expression in a human bone marrow stromal cell line. Biochem Biophys Res Commun 1992;182:310–317
20. Sethi JK, Vidal-Puig A. Wnt signalling and the control of cellular metabolism. Biochem J 2010;427:1–17